Novo Nordisk (NVO) ended the Wegovy deal, over safety and regulatory issues & HIMS tanked -34% HIMS stock just saw a massive one-day drop, and traders are asking: is this a buy-the-dip opportunity or a falling knife? In this video, I walk through the HIMS chart, show you key support zones, and break down the
spc@shareplanner.com
(904) 800-8420
© Copyright 2025 | SharePlanner Inc. All Rights Reserved.
Disclaimer: The information provided on this website is for educational and informational purposes only. Ryan Mallory and/or SharePlanner are not licensed financial advisors, brokers, or tax professionals. The content on this site should not be considered as financial, investment, tax, or legal advice.
All information and opinions expressed herein are based on sources believed to be accurate and reliable. However, we make no representation or warranty as to their accuracy, completeness, or reliability. Any action you take upon the information on this website is strictly at your own risk.
Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. All investors should make their own decisions based on their specific investment objectives and financial circumstances.
This site may contain links to external websites that are not provided or maintained by or in any way affiliated with Ryan Mallory and/or SharePlanner. Please note that Ryan Mallory and/or SharePlanner do not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites.
By using this website, you agree that Ryan Mallory and/or SharePlanner and any affiliated parties are not responsible for any losses or damages resulting from your use of or reliance on the information provided.
It is strongly recommended that you consult with a qualified professional before making any financial decisions.